Alto Neuroscience Inc (ANRO) Stock Price, Quote & News

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 200 0412

Website: www.altoneuroscience.com

Address:

650 Castro Street, Suite 450, Mountain View, United States

ALRAE Dec. 24 at 1:57 AM

$ANRO

0 · Reply

Love_To_Learn Dec. 22 at 7:09 PM

$ANRO hang on longs *

0 · Reply

Love_To_Learn Dec. 22 at 7:07 PM

$ANRO 20.64 turning it on

0 · Reply

Love_To_Learn Dec. 22 at 6:00 PM

$ANRO ive been quite generous with u for a long follower that was financially harmed by me in the past

3 · Reply

Ccperk Dec. 22 at 2:17 PM

$ANRO $35 range added to July 2026 options chain

0 · Reply

Gps_100X_ROI_Potential Dec. 21 at 10:19 PM

$ANRO $OTLK $TEAD SLS Phase 3 Registrational Results - 5 years in the making - Expected BY YEAR END - and worth 80x - 100x the current SLS Market Cap. Unblinded Interim Analysis data showed Near Miraculous ALL Pooled Survival Data - GPs Immunotherapy for AML Remission Maintenance - share price has just begun climbing, as the more realize the Best Available Treatment for the Control ARM patients, has recently Failed 3 Large Phase 3 Trials. Share Price is doing everything it should be doing as we wait for an IMMINENT Phase 3 Trial Result.

1 · Reply

Freixetes Dec. 19 at 3:49 PM

$ANRO guys, What we could expect in the next 2/3 weeks? 25/30?

0 · Reply

CARTE_BLANCHE_DEVEREAUX Dec. 18 at 9:23 PM

$ANRO Easiest call of the year. $SLS And $CING on deck. Congrats to all my longs here.

1 · Reply

Ccperk Dec. 18 at 5:36 PM

$ANRO crazy thing is they are pretty much just back to their IPO. Insanely awesome.

0 · Reply

signaljumper Dec. 18 at 5:13 PM

$ANRO 200% so far i called this Stock at my Blog the Reports are all free Update will follow at the Weekend. sign Up for free To get free Stock Reports and chartings https://www.patreon.com/posts/140493447?utm_campaign=postshare_creator&utm_content=android_share

0 · Reply

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nov 28, 2025, 12:38 PM EST - 26 days ago

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Nov 12, 2025, 7:57 AM EST - 6 weeks ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 7:34 AM EDT - 2 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 20, 2025, 7:03 AM EDT - 2 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:01 AM EDT - 2 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 8, 2025, 9:56 AM EDT - 2 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 2 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 7:34 AM EDT - 2 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Sep 13, 2025, 11:50 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 9, 2025, 7:09 AM EDT - 3 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Aug 28, 2025, 5:40 PM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 18, 2025, 9:45 AM EDT - 4 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 13, 2025, 4:10 PM EDT - 4 months ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 4, 2025, 2:46 PM EDT - 5 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Jul 22, 2025, 6:25 PM EDT - 5 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 30, 2025, 8:03 AM EDT - 6 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 26, 2025, 7:33 AM EDT - 6 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 3, 2025, 6:03 AM EDT - 7 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

May 29, 2025, 8:03 AM EDT - 7 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 14, 2025, 4:10 PM EDT - 8 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 28, 2025, 8:03 AM EDT - 8 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 22, 2025, 8:03 AM EDT - 8 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Mar 20, 2025, 4:10 PM EDT - 9 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 1, 2025, 11:00 AM EST - 10 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Feb 19, 2025, 8:03 AM EST - 11 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 12, 2025, 8:03 AM EST - 11 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 2, 2025, 11:00 AM EST - 11 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

ALRAE Dec. 24 at 1:57 AM

$ANRO

0 · Reply

Love_To_Learn Dec. 22 at 7:09 PM

$ANRO hang on longs *

0 · Reply

Love_To_Learn Dec. 22 at 7:07 PM

$ANRO 20.64 turning it on

0 · Reply

Love_To_Learn Dec. 22 at 6:00 PM

$ANRO ive been quite generous with u for a long follower that was financially harmed by me in the past

3 · Reply

Ccperk Dec. 22 at 2:17 PM

$ANRO $35 range added to July 2026 options chain

0 · Reply

Gps_100X_ROI_Potential Dec. 21 at 10:19 PM

1 · Reply

Freixetes Dec. 19 at 3:49 PM

$ANRO guys, What we could expect in the next 2/3 weeks? 25/30?

0 · Reply

CARTE_BLANCHE_DEVEREAUX Dec. 18 at 9:23 PM

$ANRO Easiest call of the year. $SLS And $CING on deck. Congrats to all my longs here.

1 · Reply

Ccperk Dec. 18 at 5:36 PM

$ANRO crazy thing is they are pretty much just back to their IPO. Insanely awesome.

0 · Reply

signaljumper Dec. 18 at 5:13 PM

0 · Reply

S_Franconi Dec. 18 at 4:05 PM

$ANRO Very Bullish.

0 · Reply

brandoppsx Dec. 18 at 8:45 AM

$ANRO I could have held here for longer and I would have broken 1 mill....instead I moved my small profit from here to $BULL and...well...I'm down 100k instead. Good times :D

2 · Reply

RunnerSignals Dec. 17 at 5:38 PM

New Highs New Stories $DBVT $ANRO $UBS $VOD $SQM are all printing fresh 52-week highs. Different sectors, same message: momentum is awake. Not chasing just watching where smart money leans https://stocksrunner.com/news/2025-12-17-52-week-high-breakout-stocks-showing-fresh-momentum

0 · Reply

Ccperk Dec. 17 at 2:32 PM

$ANRO critical top line data for two products are due 1H 2026, another is due 2H 2026. Another product has phase 2b initiation in 1H. 2026 may be one for the records books, we’ll see. I’ve never witnessed a biopharma manage their IPO money as well as this company, no fluff.

0 · Reply